Most Viewed Articles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Most Viewed Articles

Elan to Spin Off Discovery Sciences

August 13, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Elan Corporation announced plans to spin off its discovery unit and Neotope Biosciences division to create an independent entity focused on R&D.

Pfizer Settles with DOJ and SEC on Improper Conduct in Select Emerging Markets

August 7, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

An internal investigation and voluntary disclosure by Pfizer led to a settlement with the US Department of Justice and Securities and Exchange Commission.

Carbon Measurement Methods for Cleaning Validation (Peer Reviewed)

August 2, 2012

Pharmaceutical Technology

The authors compare direct combustion with rinse and swab sampling methods.

Measuring Growth in Big Pharma's Manufacturing Investment

August 2, 2012

Pharmaceutical Technology

Pharmaceutical Technology's annual manufacturing investment update shows slight gains in biopharmaceutical manufacturing and emerging markets and continued restructuring of supply networks.

Pharmaceutical-Based Cargo Security and Theft Prevention

August 2, 2012

Pharmaceutical Technology

The author discusses strategies for preventing cargo theft.

Drug Delivery Insights: Nanotechnology and Microspheres

August 1, 2012

PTSM: Pharmaceutical Technology Sourcing and Management

Nanolipogels for anticancer drug delivery, inhalable and thermo-responsive, fat-encased nanoparticles for targeted drug delivery, and calcium carbonate microspheres are some recent developments.

Medicines Top EU's Counterfeit List

July 30, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

A report from the European Commission shows that fake pharmaceuticals were the top articles detained by European Union customs in 2011.

AstraZeneca Restructures Vaccines R&D and Operations

July 24, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

MedImmune, the global biologics arm of AstraZeneca, announced that it is restructuring its infectious disease and vaccines R&D and operations. This will result in the closure of MedImmune's sites in Mountain View and Santa Clara, California.

Sandoz Completes Acquisition of Generic Dermatology Company Fougera for $1.5 billion

July 23, 2012

ePT--the Electronic Newsletter of Pharmaceutical Technology

Sandoz announced it has completed the acquisition of Fougera Pharmaceuticals, a maker of generic dermatology products, for $1.5 billion.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here